Key Inclusion Criteria:  Male or female patients aged ≥18 years with documented diagnosis of any of the following types of inherited EB: Simplex, Junctional, Dystrophic, Kindler. Enrolment will be extended to patients ≥12 years old and <18 years old after positive opinion of a data monitoring committee after at least 4 adult patients have completed study. Presence of at least 1 pair of well-matched index areas. Up to 2 pairs of index areas (1 pair of non-wound and 1 pair of wound index areas) can be selected in each patient  For non-wound itch index areas, both areas should:  Have chronic itch with a score ≥40 mm on a 100 mm VAS Not exceed 20 percent of body surface area (BSA) or be less than 1 percent of BSA Be similar size, up to twice the area of the smaller index area  For wound index areas, both wounds should:  Have a surface area ≥5 cm^2 and ≤50 cm^2 inclusive and be aged ≥3 weeks Be well matched for size (up to twice the area of the smaller index area) and age (both either ≥3 weeks to 3 months or >3 months) Female patients of childbearing potential or men whose sexual partners are women of childbearing potential (WOCBP) must use highly effective birth control WOCBP must have a negative urine pregnancy test result at baseline Must provide written consent (or assent for patients aged <18 years with parental/guardian consent)  Key Exclusion Criteria:  EB index areas have evidence of infection Patient has a systemic infection or used systemic antibiotics for EB-related infections within 7 days Use of systemic corticosteroids within 30 days or of topical corticosteroids on chosen index areas within 14 days Immunosuppressive therapy or cytotoxic chemotherapy within 60 days Use of any high potency opioid within 30 days Use of cannabis, cannabis extracts, or any cannabinoid products for medical or recreational use by any route of administration within 2 weeks Prior stem cell transplant or gene therapy for EB History of malignancy including basal cell and squamous cell carcinomas Arterial or venous disorder resulting in ulcerated wounds Uncontrolled diabetes mellitus Chronic pruritus primarily attributable to pathologies or conditions other than EB Blood transfusion to treat anemia within the past 3 months Use of any investigational drug within 30 days or 5 half-lives (whichever is longer) An underlying condition which places the patient at unacceptable risk Women who are pregnant, breastfeeding (lactating), or planning to become pregnant during the study